RCT(randomized control trial) for effectiveness of Tranexamic acid for type II endoleak after endovascular aneurysm repair

RCT(randomized control trial) for effectiveness of Tranexamic acid for type II endoleak after endovascular aneurysm repair - Tranexamic acid for type II endoleak

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015986

Enrollment

200

Registered

2015-01-01

Start date

2015-06-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Abdominal aortic aneurysm

Interventions

Tranexamic acid 750 mg/day for 6 months after EVAR Non-administration of Tranexamic acid

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: EVAR cases for Abdominal aortic aneurysm Consent cases for this study

Exclusion criteria

Exclusion criteria: Rupture cases History of thrombosis Allergy for Tranexamic acid Impossible for follow up

Design outcomes

Primary

Measure	Time frame
Frequency of type II endoleak after EVAR (Number of patients)	—

Secondary

Measure	Time frame
1 Changing aneurysm size 2 Frequency of re-intervention 3 Biomarker MMP-9 IFN-r IL-6 D-dimer FDP PAI-1 TGF-B PIC	—

Countries

Japan

Contacts

Public ContactMasaaki Kato

Morinomiya Hospital Dept. of Cardiovascular Surgery

mkato3@gmail.com06-6969-0111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026